Actively Recruiting
Study Comparing Reduced Versus Standard Dose Post-transplantation Cyclophosphamide in Combination With Post-engraftment Anti-thymoglobin as Graft Versus Host Disease Prophylaxis in Alternative Donor Peripheral Stem Cell Transplantation
Led by Shanghai Jiao Tong University School of Medicine · Updated on 2026-03-17
316
Participants Needed
1
Research Sites
182 weeks
Total Duration
On this page
Sponsors
S
Shanghai Jiao Tong University School of Medicine
Lead Sponsor
S
Shanghai Jiao Tong University Affiliated Sixth People's Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a multi-center randomized study to compare the reduced-dose of post-transplantation cyclophosphamide (PTCY) at 35mg.kg to standard dose at 50mg/kg combined with tacrolimus and post-engraftment low dose anti-thymoglobin (ATG) as graft versus host disease (GVHD) prophylaxis in patients undergoing allogeneic stem cell transplantation from alternative donor.
CONDITIONS
Official Title
Study Comparing Reduced Versus Standard Dose Post-transplantation Cyclophosphamide in Combination With Post-engraftment Anti-thymoglobin as Graft Versus Host Disease Prophylaxis in Alternative Donor Peripheral Stem Cell Transplantation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients undergoing allogeneic hematopoietic stem cell transplantation with matched unrelated or haplo-identical donor
- Normal organ function including creatinine clearance 65 ml/min/1.73m2 or creatinine 62 mg/dL
- Normal liver function with ALT and AST 62.5 times normal and total bilirubin 61.5 times normal
- Normal pulmonary function with FEV1, FVC, and DLCO 60%
- Normal cardiac function with ejection fraction 60%
- ECOG performance status of 0 to 2
- Life expectancy of at least 3 months
- Informed consent provided
You will not qualify if you...
- Pregnancy
- Active hepatitis with HBV-DNA 651 �d7 10^3 copies/ml
- Active infection requiring antibiotics
- HIV infection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ruijin hsopital
Shanghai, Shanghai Municipality, China, 200025
Actively Recruiting
Research Team
J
Jiong HU
CONTACT
L
Li-ning Wang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here